Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables - Other (2022 - 2024)

Historic Receivables - Other for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Q3 2024 value amounting to $70000.0.

  • Corvus Pharmaceuticals' Receivables - Other changed N/A to $70000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $70000.0, marking a year-over-year change of. This contributed to the annual value of $26000.0 for FY2023, which is 9557.82% down from last year.
  • Corvus Pharmaceuticals' Receivables - Other amounted to $70000.0 in Q3 2024.
  • In the past 5 years, Corvus Pharmaceuticals' Receivables - Other registered a high of $588000.0 during Q4 2022, and its lowest value of $26000.0 during Q4 2023.
  • In the last 3 years, Corvus Pharmaceuticals' Receivables - Other had a median value of $373000.0 in 2022 and averaged $269222.2.
  • Over the last 5 years, Corvus Pharmaceuticals' Receivables - Other had its largest YoY gain of 1501.34% in 2023, and its largest YoY loss of 9557.82% in 2023.
  • Quarter analysis of 3 years shows Corvus Pharmaceuticals' Receivables - Other stood at $588000.0 in 2022, then plummeted by 95.58% to $26000.0 in 2023, then surged by 169.23% to $70000.0 in 2024.
  • Its Receivables - Other stands at $70000.0 for Q3 2024, versus $35000.0 for Q2 2024 and $26000.0 for Q1 2024.